Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00961571 · ClinicalTrials.gov registry record · Phase 2
Sunitinib and Capecitabine for First Line Colon Cancer
A Phase 2 study, sponsored by Georgetown University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00961571 is a Phase 2 study that was terminated before completion, run by Georgetown University. The registered enrollment target is 50 participants.
The verdict
NCT00961571, a Phase 2 study, was terminated before completion, sponsored by Georgetown University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
This study is for patients with metastatic colorectal cancer who have not been treated with chemotherapy for their cancer. The purpose of this study is to find out if Capecitabine and Sunitinib can be used together to improve progression-free survival in colorectal cancer. All patients will take two medicines (Sunitinib and Capecitabine) by mouth every day until their cancer gets worse.
Interventions
- DRUG sunitinib and capecitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2009-08 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00961571
The ClinicalTrials.gov registry entry for NCT00961571 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sunitinib and capecitabine is the first listed.
NCT00961571 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00961571 about?
NCT00961571 is a clinical study titled "Sunitinib and Capecitabine for First Line Colon Cancer". This study is for patients with metastatic colorectal cancer who have not been treated with chemotherapy for their cancer. The purpose of this study is to find out if Capecitabine and Sunitinib can be used together to improve progression-free survival in colorectal cancer. All patients will take tw...
What is the current status of trial NCT00961571?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2009-08. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00961571?
The interventions under investigation include: sunitinib and capecitabine (DRUG).
Who is sponsoring clinical trial NCT00961571?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.